Harold R. Collard, M.D.
, and Talmadge E. King, Jr., M.D.
Dr. Collard is Assistant Clinical Professor and Dr. King is Professor and Chair, Department of Medicine, UCSF School of Medicine, San Francisco, California.
Within the past 12 months, Dr. Collard has been a consultant to InterMune and Dr. King has been a consultant to Alexz, Actelion, AstraZeneca, Biogen,
Boehringer Ingelheim, Centocor, CoTherix, FibroGen, GlaxoSmithKline, Genentech, Genzyme, Human Genome Sciences, InterMune, Merck, Millennium Pharmaceutical, Nekta, Otsuka America and Serono International.
Estimated time to complete:
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
Upon completion of this Cyberounds®
, you should be able to:
- Discuss the current approach to the diagnosis of idiopathic pulmonary fibrosis
- Describe the natural history of idiopathic pulmonary fibrosis and how to approach prognosis
- Describe the data behind potential therapies for idiopathic pulmonary fibrosis and establish an approach to management that is evidence-based.